Nektar Therapeutics Aktie News

Results from Nektar Therapeutics' phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market is projected to reach $28.7 billion by 2031. NKTR's results from phase 2b REZOLVE-AA, using REZPEG for the treatment of patients with Alopecia Areata, expected in the 2nd half of 2025.

Brand emphasizes absolute transparency and traceability, sourcing single-ingredient food from small artisan producers Brand emphasizes absolute transparency and traceability, sourcing single-ingredient food from small artisan producers

SAN FRANCISCO , May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City on May 20, 2025: H.C.

Nektar Therapeutics (NASDAQ:NKTR ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive Officer Jonathan Zalevsky – Chief Research and Development Officer Sandra Gardiner – Chief Financial Officer Conference Call Participants Dominic Risso-Gill – Piper Sandler Julian Harrison – BTIG Jay Ol...

SAN FRANCISCO , May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024.

SAN FRANCISCO , May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m.

SAN FRANCISCO , March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C.

Nektar Therapeutics (NASDAQ:NKTR ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Brian Kotzin - Interim Chief Medical Officer Jonathan Zalevsky - Chief Research & Development Officer Sandra Gardiner - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sand...